Quick Answer
LENZ Therapeutics, Inc. reported Net Income Loss of -$82.13 million for the year ending 2025.
- LENZ Therapeutics, Inc. showed a decrease of -65.0% in Net Income Loss from 2024 to 2025.
- This data is from LENZ Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2021 to 2025), LENZ Therapeutics, Inc.'s Net Income Loss has declined by 16.1%.
- Historical annual values: Fiscal year 2025: -$82.13 million | Fiscal year 2024: -$49.77 million | Fiscal year 2023: -$69.97 million | Fiscal year 2022: -$101.05 million | Fiscal year 2021: -$70.76 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: